Sitka Biopharma

Sitka Biopharma

Sitka Biopharma

Sitka Biopharma is developing a new bladder #cancer treatment - a polymer compound that allows taxane drugs to adhere to the bladder wall.
Type
B2b
Founded
2013
Raised
$4.3M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$1,900,000
Venture capital - 2018
Global Health Sciences Fund (GHS)
$2,400,000
Seed fund - 2017
Quark Venture
Team Size
2
Employees
Location
Headquarters
$1,900,000 Venture capital
FinSMEs

Sitka Biopharma Raises $1.9M in Funding

Health
$2,400,000 Seed fund
Quark Venture

Quark Venture’s early investment in Sitka Biopharma helps the Vancouver-based company advance to clinical trials